Lets just start by saying that this is where the market...

Lets just start by saying that this is where the market perception of Invion's worth is one cause for the pathetic sp we are now seeing.
Extract from Delaware Online re oral Nadalol for smoking cessation:
"Nadolol is potentially harmful for people with lung disease, a contra-indication Invion hopes to challenge by developing a gradual increase in dosage that can be patented and sold in the next two years at a total market value between $500 million and $1 billion in the United States alone."


Inhaled version,keeping in mind this is the only drug that will heal the lungs by blocking mucus production which is the major cause of death in asthma ,copd and cystic fibrosis and can also be combined with other lung medications.So this will be first in class in a $50B plus market.

"A year earlier, AstraZeneca acquired Pearl Therapeutics for up to $1.15 billion after the private, California-based company raised $232 million over six years to take a repurposed generic to late-stage trial for the treatment of COPD.
Chris Yochim, a former head of external relations for AstraZeneca and the current chairman of the Delaware BioScience Association, said Invion is well positioned to follow suit." --( And this was only after completing Phase II)
So lets say ours maybe be worth north of $1.15 B

"Repurposing drugs, from big pharma's perspective, is a concept whose time has come, and they look to extract value from all their products – including those that might have been shelved in years past – by working with small, nimble companies that are able to develop new ways to apply those assests," he said. "Mitchell is one of the unsung superheroes and there is real potential that Invion will see huge demand for its drugs once they reach proof of concept." ( Proof of concept has been achieved.)


Re Zafirlukast:
"Turning it into an inhalable has proven to be a difficult nut to crack, but we've partnered with a company – which we'll announce very soon – that has formulated it into a dry powder inhaler," he said. "We've already had two companies take a good look at it, and they say sales figures will start with a b."

Cpn10 ia an unknown value!

So are we really only worth between$20-$80 million.I'm sure Mitchell would not get out of bed or retirement for for this amount.

Had a chat to Bill Garner after agm and added that if listed on the Nasdaq we would currently be looking at dollars per share.
It is no wonder Australian Biotech companies eventually go os.No support here!